Exact Mass: 407.16348480000005
Exact Mass Matches: 407.16348480000005
Found 472 metabolites which its exact mass value is equals to given mass value 407.16348480000005
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Trifluoperazine
C21H24F3N3S (407.16429400000004)
Trifluoperazine is only found in individuals that have used or taken this drug. It is a phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics KEIO_ID T122; [MS2] KO009263 KEIO_ID T122
Cefzil
C18H21N3O6S (407.11510060000006)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DC - Second-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Anlotinib
C23H22FN3O3 (407.16451140000004)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
Sitagliptin
C16H15F6N5O (407.11807319999997)
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
gamma-L-Glutamyl-gamma-L-glutamyl-L-methionine
gamma-L-Glutamyl-gamma-L-glutamyl-L-methionine is found in pulses. gamma-L-Glutamyl-gamma-L-glutamyl-L-methionine is isolated from the seeds of Phaseolus radiatus var. typicus. Isolated from the seeds of Phaseolus radiatus variety typicus. gamma-L-Glutamyl-gamma-L-glutamyl-L-methionine is found in pulses.
8-Carboxymethyldihydrochelerythrine
C23H21NO6 (407.13688060000004)
8-Carboxymethyldihydrochelerythrine is found in fruits. 8-Carboxymethyldihydrochelerythrine is an alkaloid reported to occur in Zanthoxylum simulans (Szechuan pepper
4-Methyl Erlotinib Hydrochloride
N-[2-[(2-Oxoazepan-3-yl)carbamoyl]phenyl]-1-benzothiophene-2-carboxamide
C22H21N3O3S (407.13035560000003)
Ancistrocladine
C25H29NO4 (407.20964740000005)
Anlotinib
C23H22FN3O3 (407.16451140000004)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
Dansyl-L-arginine
C18H25N5O4S (407.16271700000004)
Dibutyryl adenosine
N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide
N-Desmethyl Topotecan
C22H21N3O5 (407.14811360000004)
n6,2'-o-dibutyryladenosine
PDE-4 Inhibitors
rac-Sitagliptin
C16H15F6N5O (407.11807319999997)
8'-(Pyridin-2-ylmethoxy)spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
C26H17NO4 (407.11575220000003)
N-phenyl[(9,11,13-trimethyl-8,15-dioxatetracyclo[10.2.2.0<2,7>.0<9,14>]hexadec a-2(7),3,5-trien-12-yl)methoxy]carboxamide
C25H29NO4 (407.20964740000005)
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.405 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.404
1-hydroxy-3,5-dimethoxy-2,4-bis-(3-methyl-but-2-enyl)-10H-acridin-9-one|atalaphylline 3,5-dimethyl ether|atalaphylline-3,5-dimethyl ether
C25H29NO4 (407.20964740000005)
4,8-dimethoxy-furo[2,3-b]quinolin-7-yl beta-D-glucopyranoside|Glucohaplin|glucohapline|glycohaplopine|O-beta-D-glucopyranosyl-haplopine
(3S,11aS)-3-[(1H-indol-3-yl)methyl]-7,9-dihydroxy-8-methoxy-2,3,11,11a-tetrahydro-6H-pyrazino[1,2-b]isoquinoline-1,4-dione
C22H21N3O5 (407.14811360000004)
4-(1,3-Dimethyl-6,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline-5-yl)-6-methyl-8-methoxynaphthalene-1-ol
C25H29NO4 (407.20964740000005)
6-O-methyl-4-O-demethylancistrocladine|6-O-methyl-4-O-demethylhamatine
C25H29NO4 (407.20964740000005)
Sitagliptin
C16H15F6N5O (407.11807319999997)
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 84 CONFIDENCE standard compound; INTERNAL_ID 2257 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2903
trazodone hydrochloride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators Trazodone hydrochloride (AF-1161) is a serotonin receptor antagonist and reuptake inhibitor. Trazodone hydrochloride can be used for the research of major depressive disorder. Trazodone hydrochloride also has potential for sleep disorder research[1].
1,5-dihydroxy-3-methoxy-10-methyl-2,4-bis(3-methylbut-2-enyl)acridin-9-one
C25H29NO4 (407.20964740000005)
C17H29NO10_2-{[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy}-3-methylbutanenitrile
trifluoperazine
C21H24F3N3S (407.16429400000004)
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics
Ala Cys Lys Ser
C15H29N5O6S (407.18384540000005)
Ala Cys Asn Thr
Ala Cys Gln Ser
Ala Cys Ser Lys
C15H29N5O6S (407.18384540000005)
Ala Cys Ser Gln
Ala Cys Thr Asn
Ala Phe Gly Asn
Ala Phe Asn Gly
Ala Gly Phe Asn
Ala Gly Asn Phe
Ala Lys Cys Ser
C15H29N5O6S (407.18384540000005)
Ala Lys Ser Cys
C15H29N5O6S (407.18384540000005)
Ala Asn Cys Thr
Ala Asn Phe Gly
Ala Asn Gly Phe
Ala Asn Thr Cys
Ala Gln Cys Ser
Ala Gln Ser Cys
Ala Ser Cys Lys
C15H29N5O6S (407.18384540000005)
Ala Ser Cys Gln
Ala Ser Lys Cys
C15H29N5O6S (407.18384540000005)
Ala Ser Gln Cys
Ala Thr Cys Asn
Ala Thr Asn Cys
Cys Ala Lys Ser
C15H29N5O6S (407.18384540000005)
Cys Ala Asn Thr
Cys Ala Gln Ser
Cys Ala Ser Lys
C15H29N5O6S (407.18384540000005)
Cys Ala Ser Gln
Cys Ala Thr Asn
Cys Gly Lys Thr
C15H29N5O6S (407.18384540000005)
Cys Gly Gln Thr
Cys Gly Thr Lys
C15H29N5O6S (407.18384540000005)
Cys Gly Thr Gln
Cys Lys Ala Ser
C15H29N5O6S (407.18384540000005)
Cys Lys Gly Thr
C15H29N5O6S (407.18384540000005)
Cys Lys Ser Ala
C15H29N5O6S (407.18384540000005)
Cys Lys Thr Gly
C15H29N5O6S (407.18384540000005)
Cys Asn Ala Thr
Cys Asn Thr Ala
Cys Gln Ala Ser
Cys Gln Gly Thr
Cys Gln Ser Ala
Cys Gln Thr Gly
Cys Ser Ala Lys
C15H29N5O6S (407.18384540000005)
Cys Ser Ala Gln
Cys Ser Lys Ala
C15H29N5O6S (407.18384540000005)
Cys Ser Gln Ala
Cys Thr Ala Asn
Cys Thr Gly Lys
C15H29N5O6S (407.18384540000005)
Cys Thr Gly Gln
Cys Thr Lys Gly
C15H29N5O6S (407.18384540000005)
Cys Thr Asn Ala
Cys Thr Gln Gly
Phe Ala Gly Asn
Phe Ala Asn Gly
Phe Gly Ala Asn
Phe Gly Gly Gln
Phe Gly Asn Ala
Phe Gly Gln Gly
Phe Asn Ala Gly
Phe Asn Gly Ala
Phe Gln Gly Gly
Gly Ala Phe Asn
Gly Ala Asn Phe
Gly Cys Lys Thr
C15H29N5O6S (407.18384540000005)
Gly Cys Gln Thr
Gly Cys Thr Lys
C15H29N5O6S (407.18384540000005)
Gly Cys Thr Gln
Gly Phe Ala Asn
Gly Phe Gly Gln
Gly Phe Asn Ala
Gly Phe Gln Gly
Gly Gly Phe Gln
Gly Gly Gln Phe
Gly Lys Cys Thr
C15H29N5O6S (407.18384540000005)
Gly Lys Thr Cys
C15H29N5O6S (407.18384540000005)
Gly Met Asn Ser
Gly Met Ser Asn
Gly Asn Ala Phe
Gly Asn Phe Ala
Gly Asn Met Ser
Gly Asn Ser Met
Gly Gln Cys Thr
Gly Gln Phe Gly
Gly Gln Gly Phe
Gly Gln Thr Cys
Gly Ser Met Asn
Gly Ser Asn Met
Gly Thr Cys Lys
C15H29N5O6S (407.18384540000005)
Gly Thr Cys Gln
Gly Thr Lys Cys
C15H29N5O6S (407.18384540000005)
Gly Thr Gln Cys
Lys Ala Cys Ser
C15H29N5O6S (407.18384540000005)
Lys Ala Ser Cys
C15H29N5O6S (407.18384540000005)
Lys Cys Ala Ser
C15H29N5O6S (407.18384540000005)
Lys Cys Gly Thr
C15H29N5O6S (407.18384540000005)
Lys Cys Ser Ala
C15H29N5O6S (407.18384540000005)
Lys Cys Thr Gly
C15H29N5O6S (407.18384540000005)
Lys Gly Cys Thr
C15H29N5O6S (407.18384540000005)
Lys Gly Thr Cys
C15H29N5O6S (407.18384540000005)
Lys Ser Ala Cys
C15H29N5O6S (407.18384540000005)
Lys Ser Cys Ala
C15H29N5O6S (407.18384540000005)
Lys Ser Ser Ser
Lys Thr Cys Gly
C15H29N5O6S (407.18384540000005)
Lys Thr Gly Cys
C15H29N5O6S (407.18384540000005)
Met Gly Asn Ser
Met Gly Ser Asn
Met Asn Gly Ser
Met Asn Ser Gly
Met Ser Gly Asn
Met Ser Asn Gly
Asn Ala Cys Thr
Asn Ala Phe Gly
Asn Ala Gly Phe
Asn Ala Thr Cys
Asn Cys Ala Thr
Asn Cys Thr Ala
Asn Phe Ala Gly
Asn Phe Gly Ala
Asn Gly Ala Phe
Asn Gly Phe Ala
Asn Gly Met Ser
Asn Gly Ser Met
Asn Met Gly Ser
Asn Met Ser Gly
Asn Ser Gly Met
Asn Ser Met Gly
Asn Ser Ser Thr
Asn Ser Thr Ser
Asn Thr Ala Cys
Asn Thr Cys Ala
Asn Thr Ser Ser
Gln Ala Cys Ser
Gln Ala Ser Cys
Gln Cys Ala Ser
Gln Cys Gly Thr
Gln Cys Ser Ala
Gln Cys Thr Gly
Gln Phe Gly Gly
Gln Gly Cys Thr
Gln Gly Phe Gly
Gln Gly Gly Phe
Gln Gly Thr Cys
Gln Ser Ala Cys
Gln Ser Cys Ala
Gln Ser Ser Ser
Gln Thr Cys Gly
Gln Thr Gly Cys
Ser Ala Cys Lys
C15H29N5O6S (407.18384540000005)
Ser Ala Cys Gln
Ser Ala Lys Cys
C15H29N5O6S (407.18384540000005)
Ser Ala Gln Cys
Ser Cys Ala Lys
C15H29N5O6S (407.18384540000005)
Ser Cys Ala Gln
Ser Cys Lys Ala
C15H29N5O6S (407.18384540000005)
Ser Cys Gln Ala
Ser Gly Met Asn
Ser Gly Asn Met
Ser Lys Ala Cys
C15H29N5O6S (407.18384540000005)
Ser Lys Cys Ala
C15H29N5O6S (407.18384540000005)
Ser Lys Ser Ser
Ser Met Gly Asn
Ser Met Asn Gly
Ser Asn Gly Met
Ser Asn Met Gly
Ser Asn Ser Thr
Ser Asn Thr Ser
Ser Gln Ala Cys
Ser Gln Cys Ala
Ser Gln Ser Ser
Ser Ser Lys Ser
Ser Ser Asn Thr
Ser Ser Gln Ser
Ser Ser Ser Lys
Ser Ser Ser Gln
Ser Ser Thr Asn
Ser Thr Asn Ser
Ser Thr Ser Asn
Thr Ala Cys Asn
Thr Ala Asn Cys
Thr Cys Ala Asn
Thr Cys Gly Lys
C15H29N5O6S (407.18384540000005)
Thr Cys Gly Gln
Thr Cys Lys Gly
C15H29N5O6S (407.18384540000005)
Thr Cys Asn Ala
Thr Cys Gln Gly
Thr Gly Cys Lys
C15H29N5O6S (407.18384540000005)
Thr Gly Cys Gln
Thr Gly Lys Cys
C15H29N5O6S (407.18384540000005)
Thr Gly Gln Cys
Thr Lys Cys Gly
C15H29N5O6S (407.18384540000005)
Thr Lys Gly Cys
C15H29N5O6S (407.18384540000005)
Thr Asn Ala Cys
Thr Asn Cys Ala
Thr Asn Ser Ser
Thr Gln Cys Gly
Thr Gln Gly Cys
Thr Ser Asn Ser
Thr Ser Ser Asn
YS121
C20H26ClN3O2S (407.1434166000001)
8-Carboxymethyldihydrochelerythrine
C23H21NO6 (407.13688060000004)
MA 20565
gamma-L-Glutamyl-gamma-L-glutamyl-L-methionine
1-amino-4-[[3-[(dimethylamino)methyl]phenyl]amino]anthraquinone, monohydrochloride
C23H22ClN3O2 (407.14004620000003)
Ezetimibe Ketone
C24H19F2NO3 (407.13329280000005)
Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. Ezetimibe is a potent cholesterol absorption inhibitor[1][2][3].
MK-2206
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C155764 - AKT Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
3-[4-(Methylsulfonyl)phenyl]-5-(1-Boc-4-piperidyl)-1,2,4-oxadiazole
C19H25N3O5S (407.15148400000004)
N-[[5-(dimethylamino)-1-naphthyl]sulphonyl]-L-alanine, compound with piperidine (1:1)
C20H29N3O4S (407.1878674000001)
Fmoc-(R)-3-Amino-4-(2-thienyl)-butyric acid
C23H21NO4S (407.1191226000001)
Fmoc-(S)-3-Amino-4-(3-thienyl)-butyric acid
C23H21NO4S (407.1191226000001)
(S)-TERT-BUTYL 3-FORMYLPYRROLIDINE-1-CARBOXYLATE
C24H19F2NO3 (407.13329280000005)
r(-)-2-(2-(diphenylphosphino)phenyl)-
C27H22NOP (407.14389320000004)
(3-(3,4-DIMETHYL-9-OXO-9H-THIOXANTHEN-2- YLOXY)-2-OH-PROPYL)TRI-ME-AMMON CL 97
C21H26ClNO3S (407.1321836000001)
R-(N-BENZYL-2-AMINO)-1-(4-METHOXYPHENYL)PROPANE (S)-MANDELIC ACID SALT
C25H29NO4 (407.20964740000005)
N,N,N,N-BIS(TETRAMETHYLENE)-O-(1,2-DIHYDRO-2-OXO-1-PYRIDYL)URONIUM HEXAFLUOROPHOSPHATE
(2S,3R)-BENZYL 3-METHYL-2-(METHYLAMINO)PENTANOATE 4-METHYLBENZENESULFONATE
C21H29NO5S (407.17663440000007)
Methanone, [4-(3,5-dimethoxyphenyl)-1-piperazinyl](5-methyl-3-phenyl-4-isoxazolyl)-
METHYL 3-(METHYLAMINO)-4-NITROBENZENECARBOXYLATE
C25H29NO4 (407.20964740000005)
Fmoc-(R)-3-Amino-4-(3-thienyl)-butyric acid
C23H21NO4S (407.1191226000001)
Crystal Violet Nonahydrate [Ion association reagent for spectrophotometric analysis]
C25H30ClN3 (407.21281300000004)
Velneperit
C78272 - Agent Affecting Nervous System > C29728 - Anorexiant Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist. Target: neuropeptide Y receptor Velneperit (S-2367) is a once-daily, oral, centrally acting, small molecule neuropeptide Y (NPY) Y5 receptor antagonist.
Fmoc-(S)-3-Amino-4-(2-thienyl)-butyric acid
C23H21NO4S (407.1191226000001)
4,11-diamine-2-[3-(1-methylethoxy)propyl]-1H-naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
C22H21N3O5 (407.14811360000004)
(S)-2-((((9H-Fluoren-9-Yl)Methoxy)Carbonyl)(Methyl)Amino)-3-Cyclohexylpropanoic Acid
C25H29NO4 (407.20964740000005)
(5aS,10bR)-5a,10b-Dihydro-2-(4-methoxyphenyl)-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate,99\\%e.e.
7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrazine
C16H15F6N5O (407.11807319999997)
(5aR,10bS)-5a,10b-Dihydro-2-(4-methoxyphenyl)-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate,99\\%e.e.
S(+)-2-[2-(DIPHENYLPHOSPHINO)PHENYL]-4-PHENYL-2-OXAZOLINE
C27H22NOP (407.14389320000004)
Inavolisib
C18H19F2N5O4 (407.14050380000003)
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D004791 - Enzyme Inhibitors > D000081082 - Phosphoinositide-3 Kinase Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
2-(4,6-Dimethylpyrimidin-2-yl)-5-((2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)carbonyl)octahydropyrrolo(3,4-C)pyrrole
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
Ciforadenant
C308 - Immunotherapeutic Agent > C2139 - Immunostimulant Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses[1].
N2-[[5-(dimethylamino)-1-naphthyl]sulphonyl]-L-arginine
C18H25N5O4S (407.16271700000004)
(1S)-1,2,3,4-Tetrahydro-8-methoxy-1alpha,3beta-dimethyl-5-[(aR)-4,5-dimethoxy-2-methyl-1-naphthalenyl]isoquinoline-6-ol
C25H29NO4 (407.20964740000005)
N-[7-(3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl)oxy-8-methyl-2-oxochromen-3-yl]acetamide
4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide
C22H21N3O3S (407.13035560000003)
ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines[1][2].
N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide
C22H21N3O5 (407.14811360000004)
5-(4-Morpholinyl)-6-nitro-2-(5,6,7,8-tetrahydronaphthalen-1-yl)isoindole-1,3-dione
C22H21N3O5 (407.14811360000004)
N-(3-chlorophenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide
3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
C23H22ClN3O2 (407.14004620000003)
(3Asr,4RS,8asr,8brs)-4-(2-(4-fluorobenzyl)-1,3-dioxodeacahydropyrrolo[3,4-A] pyrrolizin-4-YL)benzamidine
C23H24FN4O2+ (407.18831959999994)
8'-(Pyridin-2-ylmethoxy)spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
C26H17NO4 (407.11575220000003)
[(2S,3S)-2-[(1S)-1-hydroxy-2-[[(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]amino]-2-oxoethyl]-5-oxooxolan-3-yl]azanium
2-[(2E)-3,7-dimethylocta-2,6-dienyl]-3,5-dihydroxy-6-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenolate
C25H27O5- (407.18583920000003)
(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-[hydroxy(methyl)phosphoryl]butanoyl]amino]propanoyl]amino]-4-methylpentanoic acid
C16H30N3O7P (407.18212800000003)
5-[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-hydroxynonane-4,6-dione
2-({4-Chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}sulfanyl)octanoic acid
C20H26ClN3O2S (407.1434166000001)
7-(4-chlorophenyl)-2-methyl-5-oxo-4-phenyl-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid methyl ester
C24H22ClNO3 (407.1288132000001)
2-[(Z)-(2-oxo-1-propan-2-ylindol-3-ylidene)methyl]-3-phenylquinazolin-4-one
[2-(1-Piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanone
2-[5-[4-(dimethylamino)phenyl]-2-tetrazolyl]-N-[2-(4-morpholinyl)phenyl]acetamide
1-(3,4-Dichlorophenyl)-3-[1-(4-morpholinyl)-1-phenylpropan-2-yl]urea
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-2-[(6-methyl-1H-benzimidazol-2-yl)thio]acetamide
C21H21N5O2S (407.14158860000003)
Cyclohexylmethyl-[3-[1-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropyl]phosphinic acid
N-[2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine
C21H22ClN7 (407.16251220000004)
[5-[(2-Methoxyphenoxy)methyl]-3-isoxazolyl]-(4-methyl-3-phenyl-1-piperazinyl)methanone
6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one
C21H21N5O4 (407.15934660000005)
5-[4-[Methyl-[(3-methyl-2-thiophenyl)methyl]amino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester
C22H21N3O3S (407.13035560000003)
Glu-Ile-Phe
C20H29N3O6 (407.20562540000003)
A tripeptide composed of L-glutamic acid, L-isoleucine and L-phenylalanine joined in sequence by peptide linkages.
3-[1-[2-(1,3-Benzodioxol-5-yl)-1-oxoethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
C22H21N3O5 (407.14811360000004)
maremycin G
C22H21N3O3S (407.13035560000003)
An indole alkaloid with formula C22H21N3O3S. It is a natural product synthesized by an NRPS/PKS system in Streptomyces sp. B917 and exhibits antifungal properties.
5-phenyl-3-[[(1R,5S)-7-(4-phenylphenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl]methyl]isoxazole
(3S,6aR,8R,10aR)-3-hydroxy-N-(3-methoxyphenyl)-8-[2-(methylamino)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C20H29N3O6 (407.20562540000003)
[(1S)-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C20H29N3O4S (407.1878674000001)
methyl 8-[(2E)-2-[[5-[(4,5-dimethyl-1,2,4-triazol-3-yl)sulfanyl]furan-2-yl]methylidene]hydrazinyl]-8-oxooctanoate
C18H25N5O4S (407.16271700000004)
[(1R)-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C20H29N3O4S (407.1878674000001)
2-Amino-5-[[1-[(1-carboxy-2-phenylethyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
C20H29N3O6 (407.20562540000003)
(S)-benproperine trihydrogen phosphate
C21H30NO5P (407.18615000000005)
(R)-benproperine trihydrogen phosphate
C21H30NO5P (407.18615000000005)
beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN
C15H25N3O10 (407.15398700000003)
(4E)-4-[[2-(2-morpholin-4-yl-2-oxoethoxy)phenyl]methylidene]-1-phenylpyrazolidine-3,5-dione
C22H21N3O5 (407.14811360000004)
4-{[6-Endo-amino-6-exo-benzoyl-5-exo-phenylnorbornan-2-yl]oxy}-4-oxobutanoic acid
4-(3-Chlorophenyl)-1-(2-hydroxy-3,3-diphenylpropyl)piperazin-1-ium(1+)
acetylerucifoline N-oxide
A pyrrolizine alkaloid that is erucifoline in which the primary hydroxy hydrogen has been replaced by an acetyl group and the tertiary amino function has been oxidised to the corresponding N-oxide.
9-(1,3-Benzodioxol-5-yl)-6,7-dimethoxy-3,3-dimethyl-2,4,9,9a-tetrahydroacridin-1-one
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(3-hydroxy-2-methyl-4-oxobutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(3-hydroxy-3-methyl-1-oxobutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
N-[2-[(2-Oxoazepan-3-yl)carbamoyl]phenyl]-1-benzothiophene-2-carboxamide
C22H21N3O3S (407.13035560000003)
N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-D-galactosaminyl group
An N-acetyl-D-galactosaminyl group obtained by removing the hydroxy group from the hemiacetal function of N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosamine.
N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosaminyl group
N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-D-galactosaminyl group with alpha-configuration at the reducing-end anomeric centre.
LY2795050
C23H22ClN3O2 (407.14004620000003)
LY2795050 is a short-acting selective κ(kappa)-opioid receptor (KOR) antagonist. LY2795050 has high affinity for the KOR with Ki value of 0.72 nM. LY2795050 can be used for the research of central nervous system dysfunction[1][2].
TP003
TP003 is a non-selective benzodiazepine site agonist with EC50s of 20.3, 10.6, 3.24, 5.64 nM for α1β2γ2, α2β3γ2, α3β3γ2, α5β2γ2, respectively. TP003 induces anxiolysis via α2GABAA receptors[1].
(1r,4e,6s,7s,11z)-4-ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate
{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-yl}acetic acid
C23H21NO6 (407.13688060000004)
4-ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate
(5s,6s)-1',5-dimethyl-2-[(methylsulfanyl)methyl]-4,5,7,8-tetrahydrospiro[cyclopenta[f]quinoxaline-6,3'-indole]-2',3,9-trione
C22H21N3O3S (407.13035560000003)
(1r,3s)-7-(4,5-dimethoxy-2-methylnaphthalen-1-yl)-8-methoxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-ol
C25H29NO4 (407.20964740000005)
(1s,3s)-5-(4,5-dimethoxy-7-methylnaphthalen-1-yl)-8-methoxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-ol
C25H29NO4 (407.20964740000005)
(1r,4z,6s,7s,11z)-4-ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate
(2s,6'r)-7-chloro-4,6-dimethoxy-6'-methyl-4'-[(3-methylbutyl)amino]spiro[1-benzofuran-2,1'-cyclohexan]-3'-ene-2',3-dione
C21H26ClNO5 (407.1499416000001)
(3r,11ar)-1,7,9-trihydroxy-3-(3h-indol-2-ylmethyl)-8-methoxy-3h,6h,11h,11ah-pyrazino[1,2-b]isoquinolin-4-one
C22H21N3O5 (407.14811360000004)
(1r,3r)-5-(4-hydroxy-5-methoxy-7-methylnaphthalen-1-yl)-6-methoxy-1,2,3-trimethyl-3,4-dihydro-1h-isoquinolin-8-ol
C25H29NO4 (407.20964740000005)
5-({1,4-bis[(4-hydroxyphenyl)methyl]imidazol-2-yl}amino)-2-hydroxy-3-methyl-5h-imidazol-4-one
C21H21N5O4 (407.15934660000005)